Omega Fund Management, LLC
- SEC CIK
- 0001637359
- Latest filing
- Aug 14, 2026
Holdings in Q4 2021
Holdings as of Dec 31, 2021, filed Feb 14, 2022. Long positions only; changes compare share counts with Q3 2021.
- Positions
- 22
- −4 vs. Q3 2021
- Portfolio value
- $707.3M
- −$184.1M (−20.7%) vs. Q3 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| NUVBNuvation Bio Inc. | COM CL A | 22,957,340 | $195.1M | 27.6% | −5,255,036−18.6% | Reduced | History |
| REPLReplimune Group, Inc. | COM | 4,763,380 | $129.1M | 18.3% | −132,694−2.7% | Reduced | History |
| IMGOImago BioSciences, Inc. | COM | 3,018,737 | $71.6M | 10.1% | 00.0% | Unchanged | History |
| MORFMorphic Holding, Inc. | COM | 1,200,014 | $56.9M | 8.0% | −115,938−8.8% | Reduced | History |
| KRONKronos Bio, Inc. | COM | 3,818,283 | $51.9M | 7.3% | 00.0% | Unchanged | History |
| GOSSGossamer Bio, Inc. | COM | 3,164,835 | $35.8M | 5.1% | −155,773−4.7% | Reduced | History |
| IMAImageneBio, Inc. | COM | 2,249,123 | $28.2M | 4.0% | 00.0% | Unchanged | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 2,029,580 | $28.1M | 4.0% | 00.0% | Unchanged | History |
| IMUXImmunic, Inc. | COM | 1,788,160 | $17.1M | 2.4% | 00.0% | Unchanged | History |
| SANASana Biotechnology, Inc. | COM | 843,750 | $13.1M | 1.8% | 00.0% | Unchanged | History |
| ARQTArcutis Biotherapeutics, Inc. | COM | 623,836 | $12.9M | 1.8% | 00.0% | Unchanged | History |
| ICVXIcosavax, Inc. | COM | 426,395 | $9.76M | 1.4% | 00.0% | Unchanged | History |
| SPRBSpruce Biosciences, Inc. | COM | 2,161,022 | $9.64M | 1.4% | 00.0% | Unchanged | History |
| THRXTheseus Pharmaceuticals, Inc. | COM | 711,479 | $9.02M | 1.3% | +711,479 | New | History |
| PRTKParatek Pharmaceuticals, Inc. | COM | 1,971,241 | $8.85M | 1.3% | −635,568−24.4% | Reduced | History |
| SYRSSyros Pharmaceuticals, Inc. | COM | 2,512,705 | $8.19M | 1.2% | 00.0% | Unchanged | History |
| Omega Alpha SpacG6749V107 | CL A | 501,000 | $4.89M | 0.7% | 00.0% | Unchanged | – |
| EPIXESSA Pharma Inc. | COM NEW | 328,196 | $4.66M | 0.7% | 00.0% | Unchanged | History |
| IVVDInvivyd, Inc. | COM | 632,855 | $4.59M | 0.6% | 00.0% | Unchanged | History |
| CMPICheckmate Pharmaceuticals, Inc. | COM | 1,335,050 | $3.83M | 0.5% | 00.0% | Unchanged | History |
| JNCEJounce Therapeutics, Inc. | COM | 275,513 | $2.30M | 0.3% | 00.0% | Unchanged | History |
| IMCRImmunocore Holdings plc | ADS | 51,535 | $1.76M | 0.2% | 00.0% | Unchanged | History |
Sold out since Q3 2021 (5)
Positions held at the end of Q3 2021 that are gone from this filing.
| Security | Class | Shares in Q3 2021 | Value in Q3 2021 | % of portfolio in Q3 2021 | History |
|---|---|---|---|---|---|
| AVIRAtea Pharmaceuticals, Inc. | COM | 164,577 | $5.77M | 0.6% | History |
| CDTXCidara Therapeutics, Inc. | COM | 2,005,249 | $4.49M | 0.5% | History |
| OBSVObsEva SA | COM | 999,364 | $3.11M | 0.3% | History |
| TRVITrevi Therapeutics, Inc. | COM | 1,263,408 | $1.77M | 0.2% | History |
| KYNBKyntra Bio, Inc. | COM | 130,646 | $1.15M | 0.1% | History |